Sensei Biotherapeutics Inc
SNSE
Get informed when a big investor buys or sells
+ FollowMarket Cap$28.35M
Close$
$5.68
64.2% downside
Current Fair Value
64.2% downsideOvervalued by 64.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $28.35 Million |
|---|---|
| Enterprise Value | $-122,934,300.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-16.72 |
| Beta | -0.18 |
| Outstanding Shares | 1,295,052 |
Return
| Return on Equity | 134.36% |
|---|---|
| Return on Assets | -89.81% |
| Return on Invested Capital | -96.97% |
Valuation & Multiples
| P/E Ratio | -0.15 |
|---|---|
| PEG | -0.01 |
| Price to Sales | - |
| Price to Book Ratio | 0.11 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.66 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.01 |
| Debt to Equity | -0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 19, 2026
EPS Estimate
$-0.62
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 4, 2026
EPS Estimate
$-0.67
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 194.39%▲ 190.56% |
|---|---|
| Total Invested | $79.35M▲ 15314.44% |
| Investors Holding | 31▲ 21.00% |
ESG Score
No data
About Sensei Biotherapeutics Inc
31 employeesSensei Biotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company has developed a p...